首页 › 基金 › Bain Capital Life Sciences Investors, LLC › PHVS

Bain Capital Life Sciences Investors, LLC 对 PHVS 的持仓历史

PHARVARIS N V · 医疗保健

Bain Capital Life Sciences Investors, LLC 在 Q3 2026 的 13F 申报中披露持有 PHVS(PHARVARIS N V)2,475,509 股,市值约 US$76.9M,约占其申报组合的 5.30%,在其申报持仓中市值排名第 8 位。 Bain Capital Life Sciences Investors, LLC 最近 13 个申报季度中有 13 个季度披露了 PHVS 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q3 2026)2.48M 股
申报持仓市值$76.92M
组合权重5.30%
首次申报Q3 2023
最近变动减持
更新于2026-11-16

最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR

Bain Capital Life Sciences Investors, LLC 对 PHVS 的持仓演变

Bain Capital Life Sciences Investors, LLC 于 Q3 2023 首次披露 PHVS 持仓:4,784,674 股(约 US$99.9M)。 该持仓在 Q4 2023 达到峰值 3,904,319 股,市值约 US$109.5M。 在 13 次申报中,Bain Capital Life Sciences Investors, LLC 0 次增持、6 次减持、6 次保持不变。 最近一期申报(Q3 2026)显示持股 2,475,509 股、市值约 US$76.9M,环比减持 -200,000 股。。

逐季持仓明细

季度股数金额变化
Q3 2023 4.78M $99.86M 新进
Q4 2023 3.90M $109.52M 减持
Q1 2024 3.30M $76.34M 减持
Q2 2024 3.30M $62.10M 持有
Q3 2024 3.30M $61.18M 持有
Q4 2024 3.30M $63.33M 持有
Q1 2025 3.30M $51.86M 持有
Q2 2025 3.30M $58.14M 持有
Q3 2025 3.18M $79.37M 减持
Q4 2025 2.80M $77.76M 减持
Q1 2026 2.68M $75.58M 减持
Q2 2026 2.68M $92.52M 持有
Q3 2026 2.48M $76.92M 减持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 PHVS 与 13F 数据

PHVS(PHARVARIS N V)属于医疗保健行业。我们追踪的基金中还有 51 只申报持有 PHVS,申报仓位最大的包括:Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$116.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 PHVS 的基金

查看 PHVS 的全部基金持有人 →

常见问题

How long has Bain Capital Life Sciences Investors, LLC held PHVS?

Bain Capital Life Sciences Investors, LLC has disclosed PHVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bain Capital Life Sciences Investors, LLC's current position in PHVS?

As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 2.48M shares of PHVS (PHARVARIS N V), valued at $76.92M, representing 5.30% of its reported portfolio and ranking #8.

Has Bain Capital Life Sciences Investors, LLC been buying or selling PHVS?

In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC reduced its position in PHVS. The position peaked in Q4 2023 at 3.90M shares.

Which other funds hold PHVS?

Other major institutional holders of PHVS include Foresite Capital Management IV, LLC, venBio Partners LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.